U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H52N6O7.H2O4S
Molecular Weight 802.934
Optical Activity ( - )
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATAZANAVIR SULFATE

SMILES

OS(O)(=O)=O.COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C

InChI

InChIKey=DQSGVVGOPRWTKI-QVFAWCHISA-N
InChI=1S/C38H52N6O7.H2O4S/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28;1-5(2,3)4/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47);(H2,1,2,3,4)/t29-,30-,31+,32+;/m0./s1

HIDE SMILES / InChI

Molecular Formula C38H52N6O7
Molecular Weight 704.8555
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Atazanavir is the first once-daily protease inhibitor for the treatment of human immunodeficiency virus type 1 infection and should be used only in combination therapy, as part of a highly active antiretroviral therapy (HAART) regimen. In addition to being the most potent protease inhibitor in vitro, atazanavir has a distinct cross-resistance profile that does not confer resistance to other protease inhibitors. However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir.

Originator

Curator's Comment: # Novartis (before Ciba-Geigy)

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
REYATAZ

Approved Use

REYATAZ® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. The following points should be considered when initiating therapy with REYATAZ: In Study AI424-045, REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see Clinical Studies (14.2)

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4422 ng/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
6129 ng/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
2298 ng/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
5199 ng/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
46073 ng × h/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
57039 ng × h/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
14874 ng × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
28132 ng × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.6 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
18.1 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered: RITONAVIR
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
6.5 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
7.9 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
14%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ATAZANAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
30 g single, oral
Overdose
Dose: 30 g
Route: oral
Route: single
Dose: 30 g
Sources:
unhealthy, 40 years
n = 1
Health Status: unhealthy
Condition: human immunodeficiency virus
Age Group: 40 years
Sex: M
Population Size: 1
Sources:
Other AEs: Monomorphic ventricular tachycardia...
Other AEs:
Monomorphic ventricular tachycardia
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: human immunodeficiency virus
Age Group: adult
Sex: M+F
Sources:
Disc. AE: Jaundice...
Other AEs: Blood bilirubin indirect...
AEs leading to
discontinuation/dose reduction:
Jaundice (7%)
Other AEs:
Blood bilirubin indirect (33%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Monomorphic ventricular tachycardia
30 g single, oral
Overdose
Dose: 30 g
Route: oral
Route: single
Dose: 30 g
Sources:
unhealthy, 40 years
n = 1
Health Status: unhealthy
Condition: human immunodeficiency virus
Age Group: 40 years
Sex: M
Population Size: 1
Sources:
Blood bilirubin indirect 33%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: human immunodeficiency virus
Age Group: adult
Sex: M+F
Sources:
Jaundice 7%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: human immunodeficiency virus
Age Group: adult
Sex: M+F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
weak [IC50 29 uM]
yes [IC50 1.7 uM]
yes [IC50 3 uM]
yes [IC50 4.9 uM]
yes [IC50 69.1 uM]
yes [Ki 12.1 uM]
yes [Ki 12.7 uM]
yes [Ki 2.35 uM]
yes (co-administration study)
Comment: competitive and mechanism-based inhibition; administration with clarithromycin increased clarithromycin AUC by 94% and reduced 14-OH clarithromycin by 70; atazanavir increased diltiazem concentration by ~100%;
Page: 28,32
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
not significant
not significant
not significant
not significant
not significant
not significant
not significant
yes
yes (co-administration study)
Comment: 100% and 71% inhibition of ketonconazole and troleandomycin, respectively; administration with ritonavir increased atazanavir Cmax, AUC, and Cmin by 17%, 103%, and 671%, respectively;
Page: 27,29
Tox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.
2000 Aug
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
2001 Apr 1
[Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].
2001 Apr 2
BMS-232632 (Novartis/Bristol-Myers Squibb).
2001 Mar
Highlights in the development of new antiviral agents.
2002 Apr
Gateways to Clinical Trials.
2002 Apr
[New protease inhibitor atazanavir. Simple administration--less resistance].
2002 Aug 8
In vitro antiviral interaction of lopinavir with other protease inhibitors.
2002 Jul
Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.
2002 Mar-Apr
Gateways to clinical trials.
2002 Oct
[Antiretroviral therapy 2003. The current status].
2003 Apr 28
HIV therapeutics, continued: another HIV protease inhibitor approved.
2003 Aug
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
2003 Dec 5
Anti-HIV drug updates--three drugs on the near horizon.
2003 Jan
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
2003 Jan 1
[Highly effective and tolerable protease inhibitor. New trump card against HIV].
2003 Jan 16
Atazanavir: clinical use.
2003 Jul
Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
2003 Jun
Reviving protease inhibitors: new data and more options.
2003 Jun 1
New antiretroviral drugs.
2003 Mar
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
2003 May 23
Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction.
2003 May 25
Atazanavir background documents available.
2003 May 30
Three new drugs approved by FDA.
2003 Nov-Dec
Gateways to clinical trials.
2003 Oct
FDA notifications. Reyataz is approved for HIV treatment.
2003 Sep
BMS issues PK notice regarding ATV + TDF.
2003 Sep
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
2003 Sep
First once-daily protease inhibitor.
2003 Sep-Oct
Peptidomimetic inhibitors of HIV protease.
2004
Cross-resistance patterns among HIV protease inhibitors.
2004 Apr
[Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
2004 Apr 26
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
2004 Aug 15
Boosted Reyataz: 48-week results.
2004 Jan-Feb
Atazanavir: a new protease inhibitor to treat HIV infection.
2004 Jul 1
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
2004 Jun
Antiviral drugs in current clinical use.
2004 Jun
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
2004 Jun 1
Atazanavir: new option for treatment of HIV infection.
2004 Jun 1
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
2004 Mar 1
Optimizing dosing strategies for the combination of atazanavir plus saquinavir.
2004 Mar 5
Initial therapy for human immunodeficiency virus: broadening the options.
2004 Mar-Apr
New drugs of 2003.
2004 Mar-Apr
Gateways to clinical trials.
2004 May
Does atazanavir cause lipodystrophy?
2004 May
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2004 May 25
Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.
2004 Oct 15
Patents

Sample Use Guides

The recommended dose of REYATAZ ((atazanavir sulfate) capsules) is 400 mg (two 200-mg capsules) once daily taken with food. When coadministered with efavirenz, it is recommended that REYATAZ 300 mg and ritonavir 100 mg be given with efavirenz 600 mg (all as a single daily dose with food). REYATAZ without ritonavir should not be coadministered with efavirenz. When coadministered with didanosine buffered formulations, 589 REYATAZ should be given (with food) 2 hours before or 1 hour after didanosine.
Route of Administration: Oral
It was investigated the effect of atazanavir on P-glycoprotein (P-gp) expression and activity, as well as its inhibitory potency against CYP3A activity. Induction of P-gp activity and expression was studied using LS180V cells. P-gp inhibition was studied using both LS180V cells and Caco-2 cells. Extended (3-day) exposure of LS180V cells to 30 microM atazanavir caused a 2.5-fold increase in immunoreactive P-gp expression as well as a concentration-dependent decrease of intracellular Rh123 to a mean 45% (S.D. 5.2%) of control. Acute exposure (2 h) of LS180V cells to atazanavir increased intracellular Rh123 concentrations up to 300% of control at 100 microM atazanavir. At 30 microM and above, acute atazanavir exposure reversed P-gp induction caused by 3-day pretreatment with 10 microM ritonavir. P-gp inhibition was also observed in Caco-2 cells, causing an effect comparable to that observed for the known P-gp inhibitor verapamil (50% of control). In HLM, atazanavir was an inhibitor of triazolam hydroxylation, with inhibitory potency greatly increased by preincubation. IC50 values with and without preincubation were 0.31 microM (S.D. 0.13) and 5.7 microM (S.D. 4.1), respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:51:54 GMT 2023
Edited
by admin
on Fri Dec 15 15:51:54 GMT 2023
Record UNII
4MT4VIE29P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATAZANAVIR SULFATE
JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   WHO-DD   WHO-IP  
USAN  
Official Name English
EVOTAZ COMPONENT ATAZANAVIR SULFATE
Brand Name English
ATAZANAVIRI SULFAS [WHO-IP LATIN]
Common Name English
2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt)
Systematic Name English
ATAZANAVIR SULFATE [MI]
Common Name English
Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate, sulfate (1:1) (salt)
Systematic Name English
REYATAZ
Brand Name English
ATAZANAVIR SULFATE [WHO-IP]
Common Name English
ATAZANAVIR SO4 [VANDF]
Common Name English
ATAZANAVIR SULFATE [EP MONOGRAPH]
Common Name English
ATAZANAVIR SULFATE [ORANGE BOOK]
Common Name English
Atazanavir sulfate [WHO-DD]
Common Name English
NSC-742546
Code English
ATAZANAVIR SO4
VANDF  
Common Name English
ATAZOR
Common Name English
2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-, 1,14-dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1)
Systematic Name English
ATAZANAVIR SULPHATE
EMA EPAR  
Common Name English
ATAZANAVIR SULFATE [USP-RS]
Common Name English
ATAZANAVIR SULFATE [USAN]
Common Name English
BMS-232632-05
Code English
ATAZANAVIR SULPHATE [EMA EPAR]
Common Name English
ATAZANAVIR SULFATE COMPONENT OF EVOTAZ
Brand Name English
ATAZANAVIR SULFATE [MART.]
Common Name English
ATAZANAVIR SULFATE [JAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS EVOTAZ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
NCI_THESAURUS C97366
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
EMA ASSESSMENT REPORTS REYATAZ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1044334
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
NSC
742546
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
SMS_ID
100000089598
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
USAN
MM-07
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
ATAZANAVIR SULFATE
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY Description: A white to a pale yellow powder. Solubility: Freely soluble in methanol, practically insoluble in water. Category: Antiretroviral (protease inhibitor). Storage: Atazanavir sulfate should be kept in a tightly closed container. Additional information: Atazanavir sulfate is slightly hygroscopic and may exhibit polymorphism. Requirement: Atazanavir sulfate contains not less than 98.0% and not more than 102.0% of C38H52N6O7?H2SO4, calculated with reference to the dried substance.
FDA UNII
4MT4VIE29P
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
PUBCHEM
158550
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
ChEMBL
CHEMBL1163
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
CHEBI
31243
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
CAS
229975-97-7
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
NCI_THESAURUS
C28835
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
EPA CompTox
DTXSID401017206
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
DAILYMED
4MT4VIE29P
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
DRUG BANK
DBSALT000426
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
RXCUI
358299
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY RxNorm
EVMPD
SUB20595
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY
MERCK INDEX
m2119
Created by admin on Fri Dec 15 15:51:54 GMT 2023 , Edited by admin on Fri Dec 15 15:51:54 GMT 2023
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
http://apps.who.int/phint/pdf/b/Jb.6.1.36.pdf